Skip to content
    Clinical Trials

    HERMES Trial Supports Shortened SBRT Schedule Without Added Toxicity in Prostate Cancer

    LawrenceCancer

    HERMES Trial Supports Shortened SBRT Schedule Without Added Toxicity in Prostate Cancer
    The HERMES trial evaluated a shortened stereotactic body radiation therapy (SBRT) schedule for patients with prostate cancer. Findings support the use of this condensed regimen, demonstrating that it achieves treatment delivery without incurring added toxicity for patients with prostate cancer.

    Key Takeaways

    • The HERMES trial supports a shortened stereotactic body radiation therapy (SBRT) schedule without increasing toxicity in patients with prostate cancer.